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Abstract
Introduction
Successful breast conserving cancer surgeries come along with tumor free resection mar-
gins and account for cosmetic outcome. Positive margins increase the likelihood of tumor
recurrence. Intra-operative fluorescence molecular imaging (IFMI) aims to focus surgery on
malignant tissue thus substantially lowering the presence of positive margins as compared
with standard techniques of breast conservation (ST). A goal of this paper is to assess the
incremental number of surgeries and costs of IFMI vs. ST.
Methods
We developed a decision analytical model and applied it for an early evaluation approach.
Given uncertainty we considered that IFMI might reduce the proportion of positive margins
found by ST from all to none and this proportion is assumed to be reduced to 10% for the
base case. Inputs included data from the literature and a range of effect estimates. For the
costs of IFMI, respective cost components were added to those of ST.
Results
The base case reduction lowered number of surgeries (mean [95% confidence interval]) by
0.22 [0.15; 0.30] and changed costs (mean [95% confidence interval]) by €-663 [€-1,584;
€50]. A tornado diagram identified the Diagnosis Related Group (DRG) costs, the proportion
of positive margins of ST, the staff time saving factor and the duration of frozen section anal-
ysis (FSA) as important determinants of this cost.
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Conclusions
These early results indicate that IFMI may be more effective than ST and through the reduc-
tion of positive margins it is possible to save follow-up surgeries–indicating further health
risk–and to save costs through this margin reduction and the avoidance of FSA.
Introduction
Breast cancer is the most common cause of cancer deaths in women in Germany. 30.8% of all
cancer incidence in women in 2012 were caused by the disease [1].
In recent years many innovative technical methods have been developed to detect and treat
breast cancer [2–5]. There are some methods applied by the surgeon, e.g. radiofrequency spec-
troscopy, which can be used to examine the margin status of a tumor during surgery [6]. To
assess the margin status the tumor with surrounding tissue is removed. In the case of having
malignant cells at the resection edge the classification is called positive margins, otherwise it is
called negative margins [7, 8]. A person with positive margins has an elevated risk for breast
cancer recurrence [9, 10]. Therefore a common consensus between surgeons is to further
resect this type of margins in order to achieve negative margins [11]. Another often used pro-
cedure of breast cancer surgery is the removal of the sentinel lymph node. Some techniques
use the fluorescent dye indocyanine green (ICG). This dye has a very high detection rate, rang-
ing from 73.1% to 100% depending on the other components of the dye [6].
The type of recurrence also plays an important role in the course of the disease. Local recur-
rence means that the tumor comes back to the place of origin after some time, whereas
regional recurrence indicates that the tumor returns to the lymph nodes near to the origins of
the tumor [12]. The worst prognosis is given in the case of metastases. This type of recurrence
occurs in the more distant parts of the body, e.g. the brain, the liver, or the bones [12]. Later
occurrence of secondary tumors is not considered in this analysis.
Various techniques for breast conserving therapy exist [13]. Beside preoperative techniques
of tumor localization especially the assessment of margins plays an important role. An often
used strategy of margin assessment is frozen section analysis (FSA). Combined with current,
standard techniques of breast conserving surgery (ST) this is chosen as the reference technique
in this study [14]. The frozen and dissected tissue is examined by a pathologist and after the
diagnosis the surgeon is informed. An advantage of this method is the fact that it can be
applied by the surgeon during surgery [15].
Intra-operative fluorescence molecular imaging (IFMI) is an innovative surgical method of
breast cancer imaging [16]. It can be used to detect the margin status and sentinel lymph
nodes during surgery. In order to make the tumor visible for the surgeon, a fluorescence
molecular agent, for example Bevacizumab-IRDye800CW containing the monoclonal anti-
body Bevacizumab targeting the vascular endothelial growth factor A, is injected into the
patient. The optical imaging system usually consists of a fluorescence and a white light camera
and the resulting images can be examined on screens at the operating room [17]. A phase I
study in which IFMI was used took place in the Netherlands; some data from this trial is used
to inform our model parameters [18]. Within this phase I study, besides patient-safety as the
primary endpoint, tumor and tumor-margin uptake of Bevacizumab-IRDye800CW could be
confirmed [19]. In image-validation, a sufficient labelling performance was demonstrated
[20]. Therefore, compared to ST, IFMI is expected to reduce the number of surgeries and the
costs as a consequence of the avoided surgeries and the avoidance of FSA.
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The objective of the study is to analyze short term effects of IFMI compared to ST by reduc-
ing the presence of positive margins after surgery. The effects considered here include the
avoided number of surgeries and the cost savings measured in incremental costs. Developing
and using a decision tree model effects could be calculated such that the study aim was
reached.
Methods
Model structure
Decision trees are a basic type of decision-analytic models, which is commonly used to assess
the short term consequences of interventions [21]. To assess the costs and consequences of
IFMI and ST, we developed a decision tree, which is illustrated in Fig 1. When designing this
decision model, we followed the good modelling practice guidelines, as published by Philips
et al. 2006 [22]. Both the IFMI and the ST strategies were implemented in the model’s tree
structure (Fig 1): Within the model structure it is accounted for the situation in which a sur-
gery has been completely finished and the pathological report indicates the probabilities of
occurrence of the two margin types [23]. IFMI is applied within the first surgery whereas for
Fig 1. Structure of the decision tree. IFMI = intra-operative fluorescence molecular imaging. ST = standard techniques of breast conserving surgery.
https://doi.org/10.1371/journal.pone.0198137.g001
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the following surgeries probabilities of the margins are assumed the same both for the IFMI
and the ST path. Due to the consensus that positive margins should be removed in most cases,
we assume a follow-up surgery in case of positive margins, whereas in case of negative margins
no further breast cancer surgery takes place [8, 24]. A third surgery is assumed to be the final
surgery if both the first and the second surgery yielded positive margins (see Fig 1).
The time horizon considered within analysis is the time between the first breast cancer sur-
gery and return to work after the last surgery needed to finally achieve negative margins.
Costs
Surgical costs are calculated from a hospital perspective. In addition, we accounted for loss of
productivity. The costs needed for calculations were mainly costs for the standard technique,
costs of the devices for surgery, staff costs, costs of the fluorescent agent Bevacizumab-
IRDye800CW, savings due to the avoidance of FSA, costs regarding the prolongation of sur-
gery due to the application of IFMI and lost productivity costs. Table 1 gives an overview of
main cost parameters used in the model. For the costs of a certain model path the respective
cost components are added up.
The costs of ST were derived as a lump sum from the German Diagnosis Related Group
(DRG) system. DRGs relevant for ST were identified using the German version of the Interna-
tional Classification of Procedures in Medicine (ICPM) which is called “Operationen- und
Prozedurenschlu¨ssel” (OPS). The DRGs then were weighted and combined according to
the frequency of occurrence among the breast conserving OPS procedure which leads to a
weighted average cost as well as an underlying averaged two dimensional matrix combining
Table 1. Parameters related to costs per surgery.
Cost category [unit] Base
case
Distribution for
probabilistic analysis
Tornado
analysis
Further sensitivity analyses Sources
Proportion of positive margins after first
surgery with IFMI
0.1 Beta (SE = 0.018) 0.075; 0.125 Relative Risks (range 0–1) multiplied
with ST reference value 0.3
[18, 32], med. experts
Proportion of positive margins after first
surgery with ST
0.3 Beta (SE = 0.051) 0.225; 0.375 0.183(SE = 0.035) [32–35]
Costs of a breast cancer surgery with
current standard techniques [€]
3,508 Gamma (SE = 175) 2,631; 4,385 2,201(SE = 110); 5,047(SE = 252) [32, 36]
Costs of change in the duration of surgery due to IFMI, input for calculation
Duration of a standard breast cancer
surgery [minutes]
59 Triangular (min = 35,
max = 83)
44.25; 73.75 35(min = 11,max = 59); 83(min = 59,
max = 107)
[32, 37]
Prolongation due to IFMI: [minutes] 10 Triangular (min = 5,
max = 15)
7.5; 12.5 - [18, 32]
Duration of frozen section analysis
[minutes]
27 Triangular (min = 13,
max = 53
20.25; 33.75 13(min = 0,max = 26);
53(min = 40,max = 66)
[32, 38]
Staff time saving factor [no dimension] 0.64 - 0.48; 0.8 0; 1 Calculation based on
med. experts, [32]
Cost of additional staff for IFMI [€] 107 Gamma (SE = 5) 80; 134 - [32, 36]
Cost per case, materials [€]
Bevacizumab-IRDye800CW 500 Gamma (SE = 25) 375; 625 800(SE = 40) [18, 32, 39]
Camera system 182 Gamma (SE = 18) 137; 228 - [18, 32]
Sterile draping 23 Gamma (SE = 2) 18; 29 - [32, 40]
Lost productivity per case [€] 521 Gamma (SE = 52) 390; 651 - [32, 41, 42]
SE = standard error, min = minimum value, max = maximum value, med. = medical, IFMI = intra-operative fluorescence molecular imaging, ST = standard techniques
of breast conserving surgery.
https://doi.org/10.1371/journal.pone.0198137.t001
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cost centers and cost categories [25]. These costs are multiplied with numbers of surgeries of a
given model path as this cost component appears in each surgery.
To account for IFMI the additional costs needed as compared to ST were calculated. As
IFMI was used for the first surgery only the respective costs are added once for the IFMI path.
Additional staff costs of IFMI were derived by multiplying the staff costs within the mentioned
matrix for ST by factors reflecting the additional staff need of IFMI. Additional staff is assumed
to be present during the whole surgical procedure.
The IFMI device was recognized with total costs of €150,000 according to the trial data.
Additionally, maintenance costs of 10% p.a. of the original price of the device were used. In
order to determine costs of the device per surgery, the operational life span of the device was
assumed to be 7 years according to standard life spans of video systems [26]. Furthermore, 200
breast conserving surgeries per year of a midsize women’s hospital were used for relating
equipment cost to surgeries [27, 28].
The application of IFMI additionally requires 10 minutes for fluorescence inspection dur-
ing surgery. Furthermore, a shortening of surgical time takes places by avoiding waiting times
for the results of FSA. To adjust for the fact that only parts of the medical staff have to stay
with the patient a staff time saving factor (range: 0–1) is multiplied with the duration of FSA.
The factor indicates the proportion of time of FSA which can be saved. Based on interviews of
two surgeons it is assumed that the senior physician’s time cannot be saved; accounting for
German wage structure this renders a staff time saving factor of 0.64 which is taken for the
base case. The difference between the prolongation and the shortening is then multiplied with
the costs per minute of surgery which is derived by dividing the weighted average matrix men-
tioned above by the expected duration of a breast conserving surgical procedure.
Taking into account productivity losses of patients, indirect costs were also calculated. If an
additional surgery is needed because of the presence of positive margins the patient has to stay
additional time in hospital and in rehabilitation before she can return to work. For indirect
costs, average wage per day is multiplied by working days lost per surgery, the proportion of
women in employment in German general population, and the quantity of surgeries of the cor-
responding model path. The working days lost between two surgeries and between the last sur-
gery and the final return to work are assumed to be 14 days each [29, 30].
An overview on the combination of cost components in each path of the model is given in
Table 2. All costs were converted in Euros where necessary using purchasing power parity
adjusted exchange rates regarding the gross domestic product [31].
Proportion of positive margins and relative risk assigned to the tree
structure
The probability of having positive margins after ST as first surgery was derived from the litera-
ture; this proportion of positive margins currently ranges between 20% and 40% [33, 34]. We
therefore implemented a baseline point estimate of 30% positive margins for ST, and assumed
a standard error of 0.051. After considering trial documentation and consultation of medical
experts, we assumed 10% positive margins after the first surgery with IFMI as the base case
[18]. This reduction by IFMI can be expressed in terms of relative risk, equaling 33.3% for the
base case. As no strong evidence is available we performed sensitivity analyses covering the
whole range of possible reductions from 0% to 30% positive margins left after the first surgery
using IFMI. Some of the cases scheduled for a second surgery need a third surgical procedure
because of the presence of positive margins. Given that in the literature estimates of a third sur-
gery, i.e. the proportion of positive margins after the second surgery, range between 6% and
13%, we implemented a point estimate of 10% and a standard error of 0.018 [23, 43–45].
Costs and effects of intra-operative fluorescence molecular imaging
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Standard errors were calculated based on the Gaussian distribution, assuming uncertainty
ranges corresponding to 95% confidence intervals. The proportion of third surgeries is both
applied to the ST and IFMI paths.
Base case scenario
Endpoints were the amount of surgeries saved and incremental costs. The incremental number
of surgeries reflects the difference in number of surgeries expected in IFMI and in ST. Using
the corresponding costs and analogous calculation, expected costs were derived for each treat-
ment path and incremental costs again calculated as the difference between the two paths.
Sensitivity analysis
The effectiveness of using IFMI as first surgery remains to be determined. We present model
results for this strategy achieving positive margins levels of 0%, 5%, 10%, 15%, 20%, 25% and
30%, corresponding to a relative risk of 0, 0.17, 0.33, 0.5, 0.67, 0.83 and 1. Both point estimates
and 95% confidence intervals were linearly interpolated to derive continuous estimates. This
approach is supported by the linear character of the model structure. Point estimators could be
derived exactly by this method whereas confidence intervals could be derived approximately.
Within one graph all other variables besides the relative risk were held constant.
For the probabilistic analysis, gamma distributions were assigned to the costs, whereas a tri-
angular distribution was used for the duration of ST, the prolongation time due to IFMI and
the shortening of time by avoiding FSA. For the cost parameters the standard error was
assumed to be 10% of the point estimator if values were more uncertain, e.g. if some critical
assumptions were made. Otherwise the standard error was set to 5% of the point estimator.
For the construction of the confidence intervals 10,000 draws from the distributions were per-
formed within Monte Carlo Simulation.
Deterministic sensitivity analyses are shown in similar graphs including confidence inter-
vals. A tornado diagram shows the ranking of relative influence of individual variables on
Table 2. Cost components linked to the model paths in the base case.
Path Cost Components
Positive margins after the first surgery, application of IFMI
1) Positive margins after the second surgery (i.e. three surgeries)
2) Negative margins after the second surgery (i.e. two surgeries)
• Costs of a breast cancer surgery
1): three times, 2): twice a
• Additional costs of an application of IFMI
(once) a
• Lost productivity (1: three times, 2: twice)
Negative margins after the first surgery, application of IFMI (i.e.
one surgery)
• Costs of a breast cancer surgery (once) a
• Additional costs of an application of IFMI
(once) a
• Lost productivity (once)
Positive margins after the first surgery, application of ST
1) Positive margins after the second surgery (i.e. three surgeries)
2) Negative margins after the second surgery (i.e. two surgeries)
• Costs of a breast cancer surgery
1): three times, 2): twice
• Lost productivity (1: three times, 2: twice)
Negative margins after the first surgery, application of ST (i.e. one
surgery)
• Costs of a breast cancer surgery (once)
• Lost productivity (once)
IFMI = Intra-operative fluorescence molecular imaging
ST = standard techniques of breast conserving surgery.
a Costs of breast cancer surgery and additional costs of an application of IFMI can be summarized as costs per IFMI-
surgery. The additional costs consist of the device, Bevacizumab and the dye, costs due to prolongation of operation
time, savings due to the avoidance of FSA, costs of a sterile draping and costs regarding additional staff
https://doi.org/10.1371/journal.pone.0198137.t002
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results. The high and the low value used to set up the tornado diagram were calculated for each
variable using the increment and the decrement of 25 percent of the mean value [32]. Across
the potential range of effectiveness of IFMI, the impact of the most influential variables is then
tested in further sensitivity analyses.
An upper limit of DRGs for sensitivity analysis could be identified from literature. The case
is described with a main diagnosis of breast cancer and the other diagnoses were non-insulin-
dependent diabetes mellitus with unspecified complications, dilated hypertrophic cardiomy-
opathy and sequelae of cerebral infarction. Further details can be taken form the source [46].
Using the two OPS codes of breast conserving surgery and lymphadenectomy this leads to a
DRG of €5,047. The lower limit could not be determined by literature such that the lowest
DRG used within the calculations of the average matrix was taken.
During ST the surgeon and the other team members have to wait for the results of patho-
logic examination of FSA. For the base case a staff time saving factor was applied to the savings
of FSA reflecting the fact that not the whole staff has to stay with the patient during waiting
time. Within another sensitivity analysis this factor is set to 1 in order to provide a scenario in
which the whole time of FSA can be saved.
Evidence suggests that 59 minutes per surgery could be seen as an expected duration of ST.
If breast reconstruction is integrated into the breast conserving operation time increases to 83
minutes [37]. Therefore we extend the duration of ST to 83 minutes in a further sensitivity
analysis and we also used the duration of 35 minutes within another analysis to account for a
shorter operation time.
Input data for the model were taken from a phase I trial completed in 2014. In order to test
alternative scenarios of recent clinical practice, both sensitivity analysis concerning a higher
cost of Bevacizumab-IRDye800CW and a lower share of positive margins found within ST
were performed. For Bevacizumab-IRDye800CW a high cost level for contrast agents was
tested [39]. Furthermore, recent findings for positive margins of ST were integrated into the
analysis [35].
According to McCahill et al. less than 100% of persons with positive margins are re-excised
and also some people with negative margins are operated again [11]. In a structural sensitivity
analysis we thus considered that both patients with positive and with negative margins have a
positive probability of being re-excised or not being re-excised after the first surgery (Fig 2).
For the following surgeries every person with positive margins is assumed to be re-excised,
whereas each person with negative margins is assumed not to be re-excised. Probabilities of
third surgeries were assumed to stay the same. In another analysis, using again data of McCa-
hill et al., we explored the effect of fourth surgeries in which the actual proportions of numbers
of breast conserving cancer surgeries without stratification by margin type are given (Fig 3).
Software
The cost matrix of a breast conserving surgery according to the German DRG-system is
derived from G-DRG-Report-Browser 2017 [36]. In order to find specific DRGs for sensitivity
analysis the DRG web grouper of the university hospital of Mu¨nster was used [47]. The model
was set up and analyzed using TreeAge Pro 2012 [48]. Some calculations and generating of fig-
ures was done using the statistical software R version 3.3.2 [49]. The structure of the model
and the structural sensitivity analyses were drawn using Microsoft PowerPoint 2010.
Results
Applying the base case relative risk of 0.33 the amount of expected surgeries per person using
IFMI is 1.11. The ST strategy results in an expected number of surgeries of 1.33. Therefore the
Costs and effects of intra-operative fluorescence molecular imaging
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incremental number of surgeries (mean [95% confidence interval]) is -0.22 [-0.30; -0.15]. The
corresponding results regarding the costs are €4,695 for IFMI and €5,358 for ST, resulting in
incremental costs of €-663 [€-1,584; €50] by linear interpolation. Results of the whole spec-
trum of relative risks calculated by linear interpolation are shown in Figs 4 and 5 in which the
base case is marked by a vertical bar.
The most important cost drivers of the intervention are shown in the tornado diagram (Fig
6). Besides the probability of having a certain margin type especially the DRG costs, the staff
time saving factor, the duration of FSA and the duration of ST play an important role.
Fig 2. Structural sensitivity analysis: Inclusion of no re-excision of positive margins, excision of negative margins. IFMI = intra-operative fluorescence molecular
imaging. ST = standard techniques of breast conserving surgery.
https://doi.org/10.1371/journal.pone.0198137.g002
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Regarding sensitivity analyses compared to the base case, increasing the DRG costs leads to
a downward shift of the incremental costs, the slope becomes steeper and uncertainty
increases. The opposite direction of the effects can be seen when the DRG costs are decreased
(Fig A in S1 Fig and Fig B in S1 Fig).
Furthermore, setting the staff time saving factor for waiting times of FSA to unity leads to a
downwards shift of the incremental costs while uncertainty increases (Fig C in S1 Fig)–on the
other hand, assuming no staff time could be saved at all would render incremental costs of
€516 [€94; €1,000] for a relative risk of 0.33. The same result also would appear if the surgeon
orders FSA after an application of IFMI in order to get additional validation regarding margin
results. If the duration of FSA is raised within analysis the incremental costs are reduced for all
relative risks while lowering the duration of FSA results in an upwards shift together with a
reduction of uncertainty (Fig D in S1 Fig and Fig E in S1 Fig). Increasing the duration of ST
Fig 3. Structural sensitivity analysis: Numbers of surgeries without margin dependency. IFMI = intra-operative fluorescence molecular imaging. ST = standard
techniques of breast conserving surgery.
https://doi.org/10.1371/journal.pone.0198137.g003
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results in an upward shift of the incremental costs together with a reduction of uncertainty,
whereas decreasing the duration of ST results in the opposite effect (Fig F in S1 Fig and Fig G
in S1 Fig). Within all sensitivity analyses described above a shift downwards of the incremental
costs features a linear influence of these variables on model results, and the costliness of IFMI
compared to ST improves independent of relative risks, whereas a shift upwards worsens it,
respectively.
Higher costs of Bevacizumab-IRDye800CW of €800 lead to an upward shift of the incre-
mental costs and the confidence intervals (Fig H in S1 Fig). In the case of a lower proportion
of positive margins within ST the slope of the incremental costs and the uncertainty predomi-
nantly decreases which results in a worsening of the costliness of IFMI, especially for the lower
relative risks (Fig I in S1 Fig).
The first case of structural sensitivity analysis describes the situation in which both re-exci-
sion of negative margins and no re-excision of positive margins are possible. In the second
Fig 4. Base case graph: Incremental numbers of surgeries of IFMI vs. ST. RR = Relative Risk.
https://doi.org/10.1371/journal.pone.0198137.g004
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case further surgeries do not depend on the type of margins after the surgery. The cost scenario
of the first case worsens the costliness of IFMI vs ST while the cost scenario of the second case
improves it (Fig J in S1 Fig and Fig L in S1 Fig). In the first structural sensitivity scenario, the
numbers of surgeries saved are also reduced respectively (Fig K in S1 Fig). Incremental num-
bers of surgeries of the second case are not shown here as the results were nearly the same as in
the base case graph.
Discussion
In our base case IFMI saves 0.22 surgeries per person scheduled to receive breast conserving
therapy. The more the proportion of positive margins was reduced by IFMI the more surgeries
could be avoided. While future trials will show stronger evidence regarding the effect of IFMI,
we developed a model framework to analyze possible results at a very early stage. Results of a
phase I study were used as a base case, rendering a first possible order of magnitude of the
Fig 5. Base case graph: Incremental costs of IFMI vs. ST. RR = Relative Risk.
https://doi.org/10.1371/journal.pone.0198137.g005
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effects of IFMI on number of surgeries and costs. In order to address uncertainty, the whole
range of possible margin reductions was investigated. By considering up to three operations
per person to finally achieve negative margins the model also covers a wide range. For more
detail, sensitivity analyses revealed the most important determinants of results, for example,
the DRG costs. These influential variables indicate need for future consideration both in
patient management as well as in data collection, for more accurate analysis. In structural
Fig 6. Tornado analysis: Incremental costs of IFMI vs. ST. DRG = Diagnosis Related Group, PM = positive margins. ST = standard techniques of breast
conserving surgery, FSA = frozen section analysis. FI = fluorescence inspection, BI = Bevacizumab-IDRye800CW.
https://doi.org/10.1371/journal.pone.0198137.g006
Costs and effects of intra-operative fluorescence molecular imaging
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sensitivity analysis it was shown that consideration of re-excisions for negative margins and no
re-excisions for positive margins reduced incremental surgeries by about a quarter as com-
pared to the base case.
One key result, the incremental costs of IFMI vs. ST are negative for the base case, i.e. the
IFMI intervention is less expensive than the strategy without IFMI, but significant only to a
slightly higher level than 5%. Within the intervention, the DRG costs, the proportion of posi-
tive margins of ST, the staff time saving factor and the duration of FSA have the highest cost
impact. Most of the sensitivity analyses showed significant negative incremental costs for rela-
tive risks below 0.33. Furthermore, higher costs of the molecular agent and a lower proportion
of positive margins within ST were tested in a sensitivity analysis. The change in the slope for
the latter indicated that the potential impact of a reduction in the share of positive margins
through the application of IFMI has diminished.
In the model, costs of IFMI have been assumed using data of a clinical trial. If IFMI will be
applied within a daily clinical practice, costs would most likely be reduced through the higher
rate of breast cancer surgeries. It is likely that e.g. costs of the contrast agent could be reduced
as higher volume can be ordered from pharmaceutical companies.
To reflect the additional costs of IFMI versus ST, some additions to the DRGs have been
implemented in the model. Financing IFMI for daily usage in hospitals in Germany would
thus most likely require a submission to the New Methods of Diagnosis and Treatment (“Neue
Untersuchungs- und Behandlungsmethoden” or NUB) procedure. By this procedure, hospitals
can negotiate extra reimbursement for new technologies of which the costs would reach
beyond the current level of DRG reimbursement [50, 51]. According to the results presented,
this would seem to be the case for IFMI.
To improve quality we referred to the checklist of Philips et al. [22]. The structure of our
model was checked by medical experts. Data for IFMI was taken directly from a team which is
involved in the application of IFMI within a phase I trial in the Netherlands whereas costs of
ST were derived from the DRG system. Sensitivity analyses were used to check model logic
and results’ consistency.
Because of short term effects being most relevant a decision tree structure seemed adequate.
Focusing on the surgical event, integration of the natural course of breast cancer by using a
Markov-model did not seem helpful. Furthermore, the linear character of the results made it
possible to construct a graph for the whole spectrum of relative risks, thus allowing for interpo-
lation and a flexible focus of the reader on areas of results considered to be relevant.
Some limitations regarding our study exist. The setting is restricted to the German context,
e.g. costs of breast cancer cases are taken from the German DRG system. A direct transfer to
other countries is not recommended without close consideration of the cost assumptions
though the model easily allows for parameter adaptation to other contexts [52]. Within the
German DRG system repeated surgeries for the same reason can lead to different types of cod-
ing, e.g. combination of the DRGs into a new single DRG [53]. As no system wide information
is available regarding the distribution of coding approaches we assume that for each surgery
the average DRG is added to the costs of a model path. The calculation for the determination
of a specific DRG within breast conserving surgery already includes the cases for two or more
surgeries. But as this DRG is reimbursed even for the single surgery cases and the same costs
would appear for a hospital for all the following surgeries we multiplied the DRG with the
numbers of surgeries for overall costs.
Another restriction is that our analysis has focused on cost consequences and on number of
surgeries while the impact on quality of life and thus quality-adjusted life time could not rea-
sonably be included at this early stage.
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Beyond, there are more possible consequences of IFMI which are difficult to quantify. For
example, reducing surgery may increase availability of time slots in operating rooms and
reduce waiting times. Or, patients who can avoid multiple operations might even enjoy better
prognosis due to earlier treatment while this would require evidence from future studies.
Effects on final positive margins would be another issue which is difficult to address due to the
lack of evidence regarding IFMI. Furthermore, false positive readings of IFMI can lead to the
excision of healthy tissue or adverse reactions to the contrast agent might occur. Another com-
plicated modeling strategy would be considering hospitals in rural areas, in which surgical effi-
ciency is less compared to hospitals of urban areas. Another limitation, this study could not
consider whether cases exist where applying the IFMI-technology could lead to more tissue
removed than needed.
Cost effectiveness strongly depends on staff time which can be saved by IFMI. Taking the
base case relative risk of 0.33, IFMI would begin to save costs significantly, if about 2/3 of costs
of surgery staff for FSA would be saved; the exact value was found between 0.66 and 0.68
depending on run of the probabilistic model. Otherwise, it would be more difficult or even
impossible to save costs. For the base case a conservative assumption has been made, however,
an accurate estimate would require an own representative survey of the workflow during
breast surgery.
Bevacizumab-IRDye800CW plays an important role within the surgical costs of IFMI. This
drug can be applied for other cancer types, and optical imaging is not restricted solely to breast
cancer [54, 55]. Being able to use IFMI for a broader range of diseases might also lead to cost
reductions due to economic effects such as learning curves–reducing time for IFMI applica-
tion–and economies of scope. Additionally, patent expiration of Bevacizumab is expected in
the United States for 2018 [56], and this is most likely to contribute to price reduction over
time.
Another area of future application of IFMI is that it seems essential in a surgical field in
which re-operations are not possible or very difficult. This is especially the case for patient
groups who incur a high risk of complications or even mortality when undergoing surgery
[57].
The aim of IFMI is to improve quality of life as a consequence of avoided surgeries. In this
early-stage analysis, we were able to indicate ranges for the amount of surgeries saved, and the
cost impacts linked to that. The model quantifies the reduction of number of surgeries for
patients, an importantly beneficial effect, depending upon the reduction of the share in posi-
tive margins. Results also indicate that IFMI might lead to cost savings, especially if waiting
times for the results of frozen section analysis can be saved. Key cost drivers were identified of
which reduction can be considered in the further development of IFMI strategies.
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